NYSE:CBMCambrex Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cambrex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $59.99 0.00 (0.00 %) (As of 12/5/2019) Add Compare Share Today's Range$59.99Now: $59.99▼$59.9950-Day Range$59.99MA: $59.99▼$59.9952-Week Range$33.80Now: $59.99▼$60.29VolumeN/AAverage Volume218,726 shsMarket Capitalization$2.02 billionP/E Ratio21.66Dividend YieldN/ABeta2.14 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingCambrex has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.00, Cambrex has a potential upside of 0.0% from its current price of $59.99.Amount of Analyst CoverageCambrex has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesCambrex has received 309 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCambrex has received 302 “underperform” votes. (Add your “underperform” vote.)Community SentimentCambrex has received 50.57% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote “Outperform” if you believe CBM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCambrex does not currently pay a dividend.Dividend GrowthCambrex does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cambrex insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.41% of the stock of Cambrex is held by insiders.Percentage Held by Institutions90.96% of the stock of Cambrex is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cambrex is 21.66, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 17.24.Price to Earnings Ratio vs. SectorThe P/E ratio of Cambrex is 21.66, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 17.93.Price to Book Value per Share RatioCambrex has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.90 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryLife Sciences Tools & Services SectorMedical Current SymbolNYSE:CBM Previous Symbol CUSIP13201110 CIK820081 Webwww.cambrex.com Phone201-804-3000Debt Debt-to-Equity Ratio0.76 Current Ratio2.37 Quick Ratio1.70Price-To-Earnings Trailing P/E Ratio21.66 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$532.09 million Price / Sales3.80 Cash Flow$3.91 per share Price / Cash Flow15.36 Book Value$19.48 per share Price / Book3.08Profitability EPS (Most Recent Fiscal Year)$2.77 Net Income$92.41 million Net Margins5.96% Return on Equity5.38% Return on Assets2.50%Miscellaneous Employees1,732 Outstanding Shares33,720,000Market Cap$2.02 billion Next Earnings DateN/A OptionableOptionable Receive CBM News and Ratings via Email Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter. Cambrex (NYSE:CBM) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Cambrex? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cambrex. How were Cambrex's earnings last quarter? Cambrex Co. (NYSE:CBM) issued its quarterly earnings data on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.69 by $0.05. The biotechnology company earned $152.05 million during the quarter, compared to analysts' expectations of $132.78 million. Cambrex had a net margin of 5.96% and a return on equity of 5.38%. Cambrex's revenue for the quarter was up 13.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.76 earnings per share. View Cambrex's earnings history. What price target have analysts set for CBM? 2 analysts have issued 12 month target prices for Cambrex's shares. Their forecasts range from $60.00 to $60.00. On average, they anticipate Cambrex's stock price to reach $60.00 in the next twelve months. This suggests a possible upside of 0.0% from the stock's current price. View analysts' price targets for Cambrex. Has Cambrex been receiving favorable news coverage? News coverage about CBM stock has trended positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cambrex earned a news impact score of 2.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Cambrex. Who are some of Cambrex's key competitors? Some companies that are related to Cambrex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Waters (WAT), Charles River Laboratories Intl. (CRL), BIO-TECHNE (TECH), Bruker (BRKR), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE). View all competitors. What other stocks do shareholders of Cambrex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), CVS Health (CVS), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Broadcom (AVGO), Walt Disney (DIS) and Under Armour (UAA). Who are Cambrex's key executives? Cambrex's management team includes the following people: Mr. Steven M. Klosk, Pres, CEO & Director (Age 62)Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy and CFO (Age 53)Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 53)Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 41)Mr. James G. Farrell, VP & Corp. Controller (Age 52) What is Cambrex's stock symbol? Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM." What is Cambrex's stock price today? One share of CBM stock can currently be purchased for approximately $59.99. How big of a company is Cambrex? Cambrex has a market capitalization of $2.02 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe. What is Cambrex's official website? The official website for Cambrex is www.cambrex.com. How can I contact Cambrex? Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected] This page was last updated on 8/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
